Abstract
Vorasidenib: A Milestone in Targeted Therapy for IDH-Mutant Lower Grade Gliomas - Efficacy, Emerging Safety Concerns, and the Call for Comprehensive Safety Evaluation.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have